BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Mirena Observational Program

Completed

Conditions: Contraception
Endometrial Hyperplasia
Estrogen Replacement Therapy
Menorrhagia

Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028)

First Posted Date: 2009-04-20

Last Posted Date: 2016-09-30

Lead Sponsor: Bayer

Target Recruit Count: 2725

Registration Number: NCT00883662

GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Levonorgestrel IUS (LCS, BAY86-5028)

First Posted Date: 2009-04-20

Last Posted Date: 2014-08-21

Lead Sponsor: Bayer

Target Recruit Count: 918

Registration Number: NCT00884260

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

Completed

Conditions: Primary Hypertension

Interventions: Drug: Ventavis (Iloprost, BAYQ6256)

First Posted Date: 2009-04-17

Last Posted Date: 2009-04-17

Lead Sponsor: Bayer

Target Recruit Count: 38

Registration Number: NCT00882947

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2009-04-16

Last Posted Date: 2012-05-30

Lead Sponsor: Bayer

Target Recruit Count: 1739

Registration Number: NCT00882453

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Completed

Conditions: Chronic Bronchitis

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-04-09

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 345

Registration Number: NCT00879008

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Completed

Conditions: Chronic Bronchitis
Disease Exacerbation

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-04-06

Last Posted Date: 2012-09-10

Lead Sponsor: Bayer

Target Recruit Count: 1206

Registration Number: NCT00876577

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Completed

Conditions: Diagnostic Imaging

Interventions: Drug: Ultravist (Iopromide, BAY86-4877)

First Posted Date: 2009-04-06

Last Posted Date: 2011-02-28

Lead Sponsor: Bayer

Target Recruit Count: 44920

Registration Number: NCT00876083

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Completed

Conditions: Hemophilia A

Interventions: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

First Posted Date: 2009-04-03

Last Posted Date: 2014-01-29

Lead Sponsor: Bayer

Target Recruit Count: 405

Registration Number: NCT00874926

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Completed

Conditions: Epidemiologic Factors

Interventions: Biological: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2009-04-02

Last Posted Date: 2014-02-20

Lead Sponsor: Bayer

Target Recruit Count: 3711

Registration Number: NCT00874640

Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding

Completed

Conditions: Menorrhagia

Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028)

First Posted Date: 2009-04-02

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 78

Registration Number: NCT00874653

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy